Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05046964 · ClinicalTrials.gov registry record
The PPHgb Study: Non-Invasive Hemoglobin Measurement
A clinical trial, sponsored by George Washington University.
- Completed
- Registry status
- 119
- Enrollment target
NCT05046964: Completed study, sponsored by George Washington University.
NCT05046964 is a clinical trial that has completed, run by George Washington University. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05046964 has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
Study Summary
This project is a prospective observational study aimed to assess the use of non-invasive hemoglobin measurement in anticipating postpartum hemorrhage and predicting estimated blood loss. The non-invasive hemoglobin device is the Radical-7 Pulse CO-Oximeter which is a spectrophotometer manufactured by Masimo, Inc. Participants in the study will be undergoing a cesarean delivery at the George Washington University Hospital and during delivery the patient will wear the device on their fingertip so that hemoglobin measurements can be continuously recorded. No changes from routine medical management will occur during the study.
Interventions
- DEVICE Masimo Radical-7 Pulse CO-Oximeter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2023-05-05 |
What the finished NCT05046964 record still lists
NCT05046964 is an observational study that tracks outcomes without assigning an intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Masimo Radical-7 Pulse CO-Oximeter is the first listed.
NCT05046964 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05046964 about?
NCT05046964 is a clinical study titled "The PPHgb Study: Non-Invasive Hemoglobin Measurement". This project is a prospective observational study aimed to assess the use of non-invasive hemoglobin measurement in anticipating postpartum hemorrhage and predicting estimated blood loss. The non-invasive hemoglobin device is the Radical-7 Pulse CO-Oximeter which is a spectrophotometer manufactured ...
What is the current status of trial NCT05046964?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2020-11-02. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT05046964?
The interventions under investigation include: Masimo Radical-7 Pulse CO-Oximeter (DEVICE).
Who is sponsoring clinical trial NCT05046964?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI